No Benefit With Ramucirumab in First-Line Gastric Cancer Tx (CME/CE)

(MedPage Today) -- Unlike phase II results, no benefit seen in progression-free or overall survival
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news